+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Multiple Sclerosis - Pipeline Review, H2 2019

  • ID: 4894265
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 1019 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • 4D Pharma Plc
  • BioApex sro
  • Denali Therapeutics Inc
  • Immunwork Inc
  • MorphoSys AG
  • Resverlogix Corp
  • MORE
Multiple Sclerosis - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Multiple Sclerosis - Pipeline Review, H2 2019, provides an overview of the Multiple Sclerosis (Central Nervous System) pipeline landscape.

Multiple sclerosis (MS) is a potentially debilitating disease in which body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between brain, spinal cord and other areas of body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of body, fatigue and slurred speech. The predisposing factors include age, gender, family history and certain infections.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Multiple Sclerosis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Multiple Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Multiple Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 14, 25, 39, 1, 189, 37 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 2 and 40 molecules, respectively.

Multiple Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Sclerosis (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Multiple Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Multiple Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Multiple Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Sclerosis (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Multiple Sclerosis (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Multiple Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 4D Pharma Plc
  • BioApex sro
  • Denali Therapeutics Inc
  • Immunwork Inc
  • MorphoSys AG
  • Resverlogix Corp
  • MORE
Introduction
Multiple Sclerosis - Overview
Multiple Sclerosis - Therapeutics Development
Multiple Sclerosis - Therapeutics Assessment
Multiple Sclerosis - Companies Involved in Therapeutics Development
Multiple Sclerosis - Drug Profiles
Multiple Sclerosis - Dormant Projects
Multiple Sclerosis - Discontinued Products
Multiple Sclerosis - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Multiple Sclerosis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Multiple Sclerosis - Pipeline by 4D Pharma Plc, H2 2019
Multiple Sclerosis - Pipeline by AB Science SA, H2 2019
Multiple Sclerosis - Pipeline by AbbVie Inc, H2 2019
Multiple Sclerosis - Pipeline by Abeome Corp, H2 2019
Multiple Sclerosis - Pipeline by Abion Inc, H2 2019
Multiple Sclerosis - Pipeline by Abivax SA, H2 2019
Multiple Sclerosis - Pipeline by Abreos Biosciences Inc, H2 2019
Multiple Sclerosis - Pipeline by Acelerox LLC, H2 2019
Multiple Sclerosis - Pipeline by Acorda Therapeutics Inc, H2 2019
Multiple Sclerosis - Pipeline by Actelion Pharmaceuticals Ltd, H2 2019
Multiple Sclerosis - Pipeline by Addex Therapeutics Ltd, H2 2019
Multiple Sclerosis - Pipeline by Aequus Pharmaceuticals Inc, H2 2019
Multiple Sclerosis - Pipeline by Affectis Pharmaceuticals AG, H2 2019
Multiple Sclerosis - Pipeline by Ahead Therapeutics SL, H2 2019
Multiple Sclerosis - Pipeline by Akaal Pharma Pty Ltd, H2 2019
Multiple Sclerosis - Pipeline by Alexion Pharmaceuticals Inc, H2 2019
Multiple Sclerosis - Pipeline by Alpha Cancer Technologies Inc, H2 2019
Multiple Sclerosis - Pipeline by Alpine Immune Sciences Inc, H2 2019
Multiple Sclerosis - Pipeline by Altheia Science SRL, H2 2019
Multiple Sclerosis - Pipeline by Amgen Inc, H2 2019
Multiple Sclerosis - Pipeline by Anavex Life Sciences Corp, H2 2019
Multiple Sclerosis - Pipeline by Ankar Pharma SL, H2 2019
Multiple Sclerosis - Pipeline by Anokion SA, H2 2019
Multiple Sclerosis - Pipeline by Antisense Therapeutics Ltd, H2 2019
Multiple Sclerosis - Pipeline by AnTolRx Inc, H2 2019
Multiple Sclerosis - Pipeline by Anvyl LLC, H2 2019
Multiple Sclerosis - Pipeline by Aphios Corp, H2 2019
Multiple Sclerosis - Pipeline by Apimeds Inc, H2 2019
Multiple Sclerosis - Pipeline by Apitope International NV, H2 2019
Multiple Sclerosis - Pipeline by Aprilbio Co Ltd, H2 2019
Multiple Sclerosis - Pipeline by Artax Biopharma Inc, H2 2019
Multiple Sclerosis - Pipeline by Asdera, H2 2019
Multiple Sclerosis - Pipeline by AstraZeneca Plc, H2 2019
Multiple Sclerosis - Pipeline by Atara Biotherapeutics Inc, H2 2019
Multiple Sclerosis - Pipeline by Athersys Inc, H2 2019
Multiple Sclerosis - Pipeline by Athira Pharma Inc, H2 2019
Multiple Sclerosis - Pipeline by Atlantic Bio Sci LLC, H2 2019
Multiple Sclerosis - Pipeline by Autoimmunity Biologic Solutions Inc, H2 2019
Multiple Sclerosis - Pipeline by Axial Biotherapeutics Inc, H2 2019
Multiple Sclerosis - Pipeline by Axxam SpA, H2 2019

List of Figures
Number of Products under Development for Multiple Sclerosis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • 4D Pharma Plc
  • AB Science SA
  • AbbVie Inc
  • Abeome Corp
  • Abion Inc
  • Abivax SA
  • Abreos Biosciences Inc
  • Acelerox LLC
  • Acorda Therapeutics Inc
  • Actelion Pharmaceuticals Ltd
  • Addex Therapeutics Ltd
  • Aequus Pharmaceuticals Inc
  • Affectis Pharmaceuticals AG
  • Ahead Therapeutics SL
  • Akaal Pharma Pty Ltd
  • Alexion Pharmaceuticals Inc
  • Alpha Cancer Technologies Inc
  • Alpine Immune Sciences Inc
  • Altheia Science SRL
  • Amgen Inc
  • Anavex Life Sciences Corp
  • Ankar Pharma SL
  • Anokion SA
  • Antisense Therapeutics Ltd
  • AnTolRx Inc
  • Anvyl LLC
  • Aphios Corp
  • Apimeds Inc
  • Apitope International NV
  • Aprilbio Co Ltd
  • Artax Biopharma Inc
  • Asdera
  • AstraZeneca Plc
  • Atara Biotherapeutics Inc
  • Athersys Inc
  • Athira Pharma Inc
  • Atlantic Bio Sci LLC
  • Autoimmunity Biologic Solutions Inc
  • Axial Biotherapeutics Inc
  • Axxam SpA
  • Bayer AG
  • BioAegis Therapeutics Inc
  • BioApex sro
  • Biocad
  • Biocon Ltd
  • Biocure Technology Inc
  • Biogen Inc
  • BioHealthonomics Inc
  • BioIncept LLC
  • Biond Biologics Ltd
  • Bionure Farma SL
  • Biovista Inc
  • Bod Australia Ltd
  • Bolder Biotechnology Inc
  • Boston Pharmaceuticals Inc
  • BrainStorm Cell Therapeutics Inc
  • Bridge Biotherapeutics Inc
  • Bristol-Myers Squibb Co
  • BTB Pharma AB
  • Califia Bio Inc
  • Cardinal Therapeutics Inc
  • CavoGene LifeSciences
  • Celgene Corp
  • Cerion LLC
  • CGeneTech (Suzhou China) Co Ltd
  • Cinnagen Co
  • Clene Nanomedicine Inc
  • Coherus BioSciences Inc
  • Commence Bio Inc
  • Complement Pharma BV
  • Compugen Ltd
  • Convelo Therapeutics Inc
  • Corium International Inc
  • Cotinga Pharmaceuticals Inc
  • Cour Pharmaceuticals Development Co Inc
  • Curadim Pharma Co Ltd
  • CuraVac Inc
  • CuroNZ Ltd
  • Cyteir Therapeutics Inc
  • Cytocom Inc
  • Cyxone AB
  • DC4U BV
  • Denali Therapeutics Inc
  • Denceptor Therapeutics Ltd
  • DiNonA Inc
  • Disarm Therapeutics Inc
  • Domain Therapeutics SA
  • Dr. Reddy's Laboratories Ltd
  • Druggability Technologies Holdings Ltd
  • Dualogics Corp
  • EA Pharma Co Ltd
  • Eldrug SA
  • Eli Lilly and Co
  • Emerald Health Sciences Inc
  • Endece LLC
  • EnhanX Biopharm Inc
  • Enterin Inc
  • Epitracker Inc
  • Eton Pharmaceuticals Inc
  • Evgen Pharma Plc
  • F. Hoffmann-La Roche Ltd
  • Farmacija d.o.o. Tuzla
  • Fortuna Fix Inc
  • Frequency Therapeutics Inc
  • GABA Therapeutics Inc
  • Gemac SA
  • Genervon Biopharmaceuticals LLC
  • GeNeuro SA
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Glialogix Inc
  • Glixis Therapeutics LLC
  • Glixogen Therapeutics
  • Handa Pharmaceuticals LLC
  • Hibernaid Inc
  • Humabs BioMed SA
  • HuniLife Biotechnology Inc
  • Hutchison MediPharma Ltd
  • IL-2Rx Inc
  • Iltoo Pharma
  • ImCyse SA
  • Immune Response BioPharma Inc
  • Immungenetics AG
  • Immunic Inc
  • Immunwork Inc
  • ImmusanT Inc
  • Immutep Ltd
  • Imstem Biotechnology Inc
  • Inflazome Ltd
  • Inmune Bio Inc
  • InnoBioscience LLC
  • Innovimmune Biotherapeutics Inc
  • InSight Biopharmaceuticals Ltd
  • Io Therapeutics Inc
  • Istesso Ltd
  • J2H Biotech
  • Jyant Technologies Inc
  • Karo Pharma AB
  • Kintai Therapeutics Inc
  • Klogene Therapeutics Inc
  • Kogenix Therapeutics Inc
  • Kyorin Pharmaceutical Co Ltd
  • Landos Biopharma Inc
  • Lead Discovery Center GmbH
  • Leukosight Inc
  • LFB SA
  • LIFNano Rx Ltd
  • Llama Therapeutics Inc
  • Mabion SA
  • MAKScientific LLC
  • Mapi Pharma Ltd
  • Maruho Co Ltd
  • Med-Life Discoveries LP
  • MedAnnex Ltd
  • MedaRed Inc
  • MedDay SA
  • Merck KGaA
  • Meta-IQ ApS
  • MetrioPharm AG
  • Millennium Pharmaceuticals Inc
  • Mirae Cell Bio Co Ltd
  • Mitochon Pharmaceuticals Inc
  • Mitotech SA
  • Mitsubishi Tanabe Pharma Corp
  • MMJ International Holdings Corp
  • Mochida Pharmaceutical Co Ltd
  • Molecules For Health Inc
  • Momenta Pharmaceuticals Inc
  • MorphoSys AG
  • Mount Tam Biotechnologies Inc
  • NervGen Pharma Corp
  • Neuren Pharmaceuticals Ltd
  • Neuro Vigor LLC
  • Neurodegeneration Therapeutics Inc
  • Neurotrope Bioscience Inc
  • New World Laboratories Inc
  • Novartis AG
  • Novoron Bioscience Inc
  • Numab Innovation AG
  • Omeros Corp
  • Oncodesign SA
  • OncoImmune Inc
  • Op-T-Mune Inc
  • Orion Biotechnology Canada Ltd
  • Orpheris Inc
  • Oryzon Genomics SA
  • Oscine Therapeutics
  • OSE Immunotherapeutics
  • Ossianix Inc
  • Pahan Therapeutics
  • Pangen Biotech Inc
  • Par'Immune SAS
  • PharmatrophiX Inc
  • Pipeline Therapeutics Inc
  • Polpharma Biologics
  • Principia Biopharma Inc
  • Progenitor Therapeutics Ltd
  • Promethera Biosciences SA
  • ProNoxis AB
  • Proteorex Therapeutics Inc
  • Q Therapeutics Inc
  • Quimatryx SL
  • Radikal Therapeutics Inc
  • Reata Pharmaceuticals Inc
  • ReceptoPharm Inc
  • RedHill Biopharma Ltd
  • RegeneRx Biopharmaceuticals Inc
  • RemeGen Ltd
  • ReNeuroGen LLC
  • Renovo Neural Inc
  • Resverlogix Corp
  • Revalesio Corp
  • ReveraGen BioPharma Inc
  • Rewind Therapeutics NV
  • Rhizen Pharmaceuticals SA
  • Rigel Pharmaceuticals Inc
  • Riptide Bioscience Inc
  • Rodos BioTarget GmbH
  • Rubius Therapeutics Inc
  • SanBio Inc
  • Sanofi
  • Sansho Co Ltd
  • Sareum Holdings Plc
  • Scientus Pharma Inc
  • Seneca Biopharma Inc
  • Senju Pharmaceutical Co Ltd
  • SK Chemicals Co Ltd
  • Sorrento Therapeutics Inc
  • Spinalcyte Llc
  • Stem Cell Medicine Ltd
  • Sujana Biotech, LLC
  • Suzhou Connect Biopharmaceuticals Ltd
  • Symbiotix Biotherapies Inc
  • SynAct Pharma AB
  • Synthon Holdings BV
  • Takeda Pharmaceutical Co Ltd
  • Teikoku Pharma USA Inc
  • Tellus Therapeutics Inc
  • TeraImmune Inc
  • Tetra Therapeutics
  • Theratome Bio Inc
  • Tiziana Life Sciences Plc
  • Toleranzia AB
  • TolerogenixX GmbH
  • Tonix Pharmaceuticals Holding Corp
  • Topas Therapeutics GmbH
  • Transparency Life Sciences LLC
  • Trio Medicines Ltd
  • UBI Pharma Inc
  • V Clinbio LLC
  • Vaccinex Inc
Note: Product cover images may vary from those shown
Adroll
adroll